TG Therapeutics Inc (TGTX) concluded trading on Wednesday at a closing price of $39.82, with 4.48 million shares of worth about $178.45 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 70.24% during that period and on April 03, 2025 the price saw a gain of about 5.48%. Currently the company’s common shares owned by public are about 155.84M shares, out of which, 141.43M shares are available for trading.
Stock saw a price change of -2.38% in past 5 days and over the past one month there was a price change of 11.79%. Year-to-date (YTD), TGTX shares are showing a performance of 32.29% which increased to 169.60% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $12.93 but also hit the highest price of $43.32 during that period. The average intraday trading volume for TG Therapeutics Inc shares is 2.65 million. The stock is currently trading -0.09% below its 20-day simple moving average (SMA20), while that difference is up 14.06% for SMA50 and it goes to 44.63% higher than SMA200.
TG Therapeutics Inc (NASDAQ: TGTX) currently have 155.84M outstanding shares and institutions hold larger chunk of about 62.25% of that.
The stock has a current market capitalization of $6.25B and its 3Y-monthly beta is at 2.23. PE ratio of stock for trailing 12 months is 285.24, while it has posted earnings per share of $0.14 in the same period. Its PEG reads 1.83 and has Quick Ratio of 5.03 while making debt-to-equity ratio of 1.14. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TGTX, volatility over the week remained 6.99% while standing at 6.32% over the month.
Stock’s fiscal year EPS is expected to rise by 545.71% while it is estimated to increase by 98.97% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by TD Cowen on October 29, 2024 offering a Buy rating for the stock and assigned a target price of $50 to it. Coverage by Goldman stated TG Therapeutics Inc (TGTX) stock as a Neutral in their note to investors on August 02, 2023, suggesting a price target of $12 for the stock. On June 26, 2023, Jefferies Resumed their recommendations, while on May 20, 2022, BofA Securities Initiated their ratings for the stock with a price target of $5. Stock get a Buy rating from B. Riley Securities on February 23, 2022.
